ZIVOOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Zivo Bioscience, Inc.

Financials through Q3 FY2025, quarter ended Sep 30, 2025Last filing: 10-Q on Nov 14, 2025

$6.80+0.30 (+4.62%)

Close on Oct 19, 2026

Market cap: $25.96M
P/E (TTM): –
Dividend yield: –

Zivo Bioscience, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31
Revenue	0.16	0.03	0	0	0.02	0	0	0	0	0	0	0	0	0.10	0.08
Cost of Revenue	0.11	0.02	0	–	–	–	–	–	–	–	–	0	0	0.14	0.05
Gross Profit	0.05	0.01	0	–	–	–	–	–	–	–	–	0	0	-0.03	0.03
Research & Development	3.13	1.38	2.24	1.95	3.75	2.31	2.81	2.38	0.79	1.03	1.97	1.02	0.68	0.38	0.40
General & Administrative	10	5.90	6.49	6.69	4.82	4.08	1.35	2.13	0.83	0.96	1.04	1.19	0.94	0.60	1.24
Advertising Expenses	–	–	–	–	0	0	0	0	0	0	–	–	0.03	0.00	–
Operating Expenses	13	7.27	8.73	8.65	8.58	8.35	6.13	6.33	3.49	–	–	–	2.08	2.04	4.14
Total Costs & Expenses	–	–	–	–	–	–	–	–	3.49	3.06	5.15	3.11	2.08	–	–
Operating Income	-13	-7.26	-8.73	-8.65	-8.56	-8.35	-6.13	-6.33	-3.49	-3.06	-5.15	-3.11	-2.08	-1.94	-4.06
Interest Expense	–	0.02	0.01	0.04	0.10	–	–	–	-0.04	0.00	0.52	-0.44	-0.14	-0.05	-0.01
Other Non-Operating Income	–	–	-0.01	-0.11	-0.55	-3.16	-8.50	-3.71	-2.57	-2.73	–	–	-1.17	-0.79	-3.06
Net Income incl. Noncontrolling Interests	-13	-7.78	8.75	–	-9.11	-12	-15	-10	-6.06	-5.79	0.68	-10	-3.25	-2.73	-7.12
Net Income	-13	-7.78	-8.75	-8.76	-9.11	-12	-15	-10	-6.06	-5.79	0.68	-10	-3.25	-2.73	-7.12
EPS (Basic)(per share)	–	–	–	–	-1.60	-3.20	-7.20	-5.60	-4.00	-3.20	0.80	-7.20	-2.40	-2.40	-6.40
EPS (Diluted)(per share)	-4.23	-4.60	–	–	-1.60	-3.20	-7.20	-5.60	-4.00	-3.20	0.80	-7.20	-2.40	-2.40	-6.40
Shares Outstanding (Basic, Weighted)(shares)	–	–	–	–	5.08	3.45	1.96	1.74	1.67	1.64	2.28	1.40	1.27	–	–
Shares Outstanding (Diluted, Weighted)(shares)	3.17	1.69	–	–	5.08	3.45	1.96	1.74	1.67	1.64	2.28	1.40	1.27	–	–
Dividend per Share(per share)	–	3.11	–	–	–	–	–	–	–	–	–	–	–	–	–
EBITDA	–	–	–	-8.65	-8.56	-8.35	-6.13	-6.31	-3.47	-3.03	-5.13	-3.09	-2.01	-1.85	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Sep 30, 2025

Profitability, TTM

Gross margin: 31.7%
Operating margin: -4045.7%
Net margin: -4059.7%
Return on equity, FY2024: 983.9%

Financial strength

Current ratio: 0.08
Debt to equity: -0.00
Debt to assets: 2.1%
Cash to current liabilities: 1.6%

Valuation

P/E ratio: –
Price to sales: 124.18
Price to book: –
Dividend yield: –